A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma.

MLA

Kudo, Masatoshi, et al. “A Randomized, Double‐blind, Placebo‐controlled, Phase 3 Study of Tivantinib in Japanese Patients with MET‐high Hepatocellular Carcinoma.” Cancer Science, vol. 111, no. 10, Oct. 2020, pp. 3759–69. EBSCOhost, https://doi.org/10.1111/cas.14582.

APA

Kudo, M., Morimoto, M., Moriguchi, M., Izumi, N., Takayama, T., Yoshiji, H., Hino, K., Oikawa, T., Chiba, T., Motomura, K., Kato, J., Yasuchika, K., Ido, A., Sato, T., Nakashima, D., Ueshima, K., Ikeda, M., Okusaka, T., Tamura, K., & Furuse, J. (2020). A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma. Cancer Science, 111(10), 3759–3769. https://doi.org/10.1111/cas.14582

Chicago

Kudo, Masatoshi, Manabu Morimoto, Michihisa Moriguchi, Namiki Izumi, Tetsuji Takayama, Hitoshi Yoshiji, Keisuke Hino, et al. 2020. “A Randomized, Double‐blind, Placebo‐controlled, Phase 3 Study of Tivantinib in Japanese Patients with MET‐high Hepatocellular Carcinoma.” Cancer Science 111 (10): 3759–69. doi:10.1111/cas.14582.